Author:
Sink K.S.,Segovia K.N.,Sink J.,Randall P.A.,Collins L.E.,Correa M.,Markus E.J.,Vemuri V.K.,Makriyannis A.,Salamone J.D.
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology
Reference76 articles.
1. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers;Addy;J. Clin. Pharmacol.,2008
2. In-vitro and in-vivo action of cannabinoids;Akinshola;Neurochem. Res.,1999
3. Blockade of cannabinoid receptors by SR141716 selectively increases fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function;Alonso;Neuroscience,1999
4. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters;Arevalo;Pharmacol. Biochem. Behav.,2001
5. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors;Arnone;Psychopharmacology (Berl),1997
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献